Genedrive notifies FDA of its intent to distribute to SARS-CoV-2 PCR test in the USA
Genedrive PLC (GDR.L) HCV ID Kit demonstrates high clinical accuracy in India study
Hepatitis C virus testing kit reveals 100% sensitivity and specificity when compared to Abbott Realtime HCV test
Genedrive PLC (GDR.L) Notice of Results
genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces that it will release its financial results for the year ended 30 June 2020 on Tuesday 17 November 2020.
Genedrive PLC (GDR.L) Point-of-Care solution to detect SARS-CoV-2 virus
Genedrive plc (LSE: GDR), the near patient molecular diagnostics company, announces it has completed the assay design for the Company’s Point-of-Care (“POC”) solution for COVID-19 testing and is now generating
Genedrive PLC (GDR.L) Verification with Beckman Coulter Life Sciences
Genedrive® 96 SARS-CoV-2 Kit verified with Beckman Coulter Life Sciences RNA extraction chemistry
Genedrive PLC (GDR.L) Collaboration to automate COVID-19 PCR testing
Beckman Coulter collaboration to automate high throughput SARS-CoV-2 PCR testing
David Budd, Chief Executive Officer of Genedrive PLC (GDR.L) Podcast
Share Talk caught up with Manchester-based company Genedrive PLC and spoke with David Budd, CEO about the company recent announcement with the development of two coronavirus tests, one for central